South Korean firm AriBio is planning to expand global Phase III trials for its oral Alzheimer’s disease candidate following an IND approval at home. Patient enrolment in a US trial began late last year.

Korea Health Industry Development Institute President Soon-Do Cha talks to Scrip how the government agency’s support strategy to the domestic biopharma industry may be changing in line with the industry’s increased globalization move and how he views the country’s policy stance should improve going forward to meet its goal of becoming a strong biohealth nation.

Scrip wraps up major R&D and corporate developments for Korean biopharmas in 2022 and outlines what lies ahead for them in the new year.

In Vivo takes an infographic look at where South Korea stands in the development of a wide-ranging set of drugs for Alzheimer’s disease and which companies are still in the challenging race.